Pancreatic Cancer Research

ResearcherSun Yat-sen UniversityActive in the last 2 years

Ran Wei

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-5121-3650; OpenAlex author ID A5017624106. Sources: OpenAlex.

Their work

Papers
6 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
8
Papers, trials and grants by year

2022: 2 papers · 2023: 1 paper · 2024: 1 paper · 2025: 2 papers

Papers 6

  1. Niraparib perturbs autophagosome-lysosome fusion in pancreatic ductal adenocarcinoma and exhibits anticancer potential against gemcitabine-resistant PDAC. Last author DOI 10.1016/j.tranon.2024.102206↗
  2. Development of a Nomogram Integrating Modified Inflammation-Based Indexes for Predicting Overall Survival in Pancreatic Cancer: A Retrospective Study. Co-author DOI 10.2147/jir.s519779↗
  3. Nomogram for predicting post-progression-free survival in patients with recurrent pancreatic ductal adenocarcinoma after radical surgery: a retrospective analy… Co-author DOI 10.3389/fmed.2024.1486750↗
  4. Prognostic effect of CD73 in pancreatic ductal adenocarcinoma for disease-free survival after radical surgery. First author DOI 10.1007/s00432-023-04703-4↗
  5. Type 1 T Helper Cell-Based Molecular Subtypes and Signature Are Associated with Clinical Outcome in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fcell.2022.839893↗
  6. Sample-Specific Perturbation of Gene Interactions Identifies Pancreatic Cancer Subtypes. Co-author DOI 10.3390/ijms23094792↗

Closest collaborators

The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Dailei Qin · 6 shared papers, 2022–2025 · strength 1.34
  2. Zehui Yao · 4 shared papers, 2023–2025 · strength 0.96
  3. Pu Xi · 4 shared papers, 2023–2025 · strength 0.96
  4. Shengping Li · 4 shared papers, 2022–2025 · strength 0.85
  5. Lingmin Jiang · 3 shared papers, 2024–2025 · strength 0.77
  6. Shengping Li · 2 shared papers, 2024–2025 · strength 0.49
  7. Wuguo Deng · 2 shared papers, 2022 · strength 0.37
  8. Honglu Ding · 1 shared paper, 2023 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.